抗丙型肝炎病毒治疗过程中甲状腺功能异常与病毒学应答关系研究*

doi:10.3969/j.issn.1672-5069.2016.05.008

实用肝脏病杂志 ›› 2016, Vol. 19 ›› Issue (5): 540-543.doi: 10.3969/j.issn.1672-5069.2016.05.008

抗丙型肝炎病毒治疗过程中甲状腺功能异常与病毒学应答关系研究^*

朱芳, 颜学兵, 王家猛, 周付成, 费媛媛

221002江苏省徐州市徐州医科大学/宿迁市第一人民医院感染病科（朱芳,费媛媛）; 徐州医科大学附属医院感染性疾病科（颜学兵）; 宿迁市钟吾医院感染病科（王家猛,周付成）

收稿日期:2016-04-12 出版日期:2016-09-10 发布日期:2016-10-12
通讯作者: 颜学兵,E-mail: yxbxuzhou@126.com
作者简介:朱芳,女,29岁,硕士研究生,主治医师。E-mail:zhu606fang@126.com
基金资助:
国家自然科学基金项目（编号：81371867）; 江苏省医学科技专项/新型临床诊疗技术攻关项目（编号：BL2014033）; 江苏省“科教兴卫”医学重点人才培养基金项目（编号：RC2011117）; 江苏省“六大人才高峰”项目（编号：2011-WS-068）

Prevalence of thyroid dysfunction and its impact on virologic response in patients with hepatitis C receiving pegylated interferon-α and ribavirin

Zhu Fang, Yan Xuebing, Wang Jiameng, et al.

Department of Infectious Diseases,Xuzhou Medical College,Xuzhou 221002,Jiangsu Province,China

Received:2016-04-12 Online:2016-09-10 Published:2016-10-12

摘要/Abstract

摘要： 目的探讨聚乙二醇干扰素（Peg-IFN）联合利巴韦林（RBV）治疗慢性丙型肝炎患者发生甲状腺功能异常的转归及其对抗病毒疗效的影响。方法204例（HCV基因1b型感染173例,2a型9例,3b型2例,未分型20例）慢性丙型肝炎患者应用Peg-IFN联合RBV抗病毒治疗。对于基因1型和未分型者治疗48 w,对于基因2型和3型治疗24 w。采用化学发光免疫分析法检测血清游离三碘甲状腺原氨酸（FT3）、游离甲状腺素（FT4）、超敏促甲状腺激素（sTSH）;采用间接免疫荧光法检测血清抗甲状腺球蛋白抗体（Tg-Ab）、抗甲状腺过氧化物酶抗体（TPOAb）、抗促甲状腺激素受体抗体（TRAb）、抗甲状腺微粒体抗体。结果在治疗过程中,发生甲状腺功能异常43例（19.0%）,其中甲状腺功能减退症7例（16.3%）,亚临床甲状腺功能减退症17例（39.5%）,甲状腺功能亢进症11例（25.6%）,亚临床甲状腺功能亢进症8例（18.6%）;甲状腺功能异常集中发生于治疗后24~36 w;在观察结束时,37例甲状腺功能异常患者自发或者经药物治疗后甲状腺功能恢复正常,6例患者仍需要密切监测甲状腺功能或服用抗甲状腺药物;43例甲状腺功能异常与161例无甲状腺功能异常患者RVR、EVR、ETVR、SVR、治疗结束后96 w病毒学应答率差异均无统计学意义（P>0.05）。结论Peg-IFN联合RBV治疗慢性丙型肝炎患者诱发甲状腺功能异常的发生率为19.0%,大部分是可逆的,甲状腺功能异常不影响抗病毒疗效。

关键词: 慢性丙型肝炎, 聚乙二醇干扰素, 甲状腺功能, 病毒学应答

Abstract: Objective To explore the prevalence of thyroid dysfunction in patients with chronic hepatitis C during pegylated interferon（Peg-IFN） combined with ribavirin（RVB） therapy and its impact on antiviral efficacy. Methods 204 patients （HCV 1b infection in 173,2a in 9,3b in 2,and undefined in 20） with chronic hepatitis C who had normal thyroid function at the beginning of the study received the treatment of Peg-IFN combined with RBV. The regimen lasted for 48 weeks for patients with HCV 1 and undefined genotypes,and for 24 weeks for patients with genotype 2 and 3. Serum FT3,FT4,sTSH,Tg-Ab,TPOAb and TRAb were detected. Results Thyroid dysfunction occurred in 43 patients（19.0%） during the PEG-IFN/RBV treatment,among whom 16.3% presented with hypothyroidism,39.5% with subclinical hypothyroidism,25.6% with hyperthyroidism,and 18.6% with subclinical hyperthyroidism. Thyroid dysfunction mainly occurred at 24 to 36 week treatment. At the end of observation,37 patients with thyroid dysfunction recovered spontaneously or after medical intervention,however,six patients with high serum titer of thyroid autoantibodies still needed close monitoring of thyroid function and sustained administration of anti-thyroid agents. There were no significant differences as respect to RVR,EVR,ETVR and SVR between 43 patients with thyroid dysfunction and 161 with normal thyroid function（P>0.05）. Conclusion Thyroid dysfunction occurs in patients with chronic hepatitis C during Peg-IFN/RBV treatment. The thyroid dysfunctions are reversible,and do not influence the antiviral efficacy.

Key words: Hepatitis C, Thyroid function, Pegylated interferon, Virologic response

朱芳, 颜学兵, 王家猛, 周付成, 费媛媛. 抗丙型肝炎病毒治疗过程中甲状腺功能异常与病毒学应答关系研究^*[J]. 实用肝脏病杂志, 2016, 19(5): 540-543.

Zhu Fang, Yan Xuebing, Wang Jiameng, et al.. Prevalence of thyroid dysfunction and its impact on virologic response in patients with hepatitis C receiving pegylated interferon-α and ribavirin[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(5): 540-543.

参考文献

[1] 中华医学会肝病学分会,中华医学会感染病学分会.丙型肝炎防治指南（2015更新版）. 中华肝脏病杂志,2015,23（12）:906-923.
[2] Tomer Y,Blackard JT,Akeno N. Interferon alpha treatment and thyroid dysfunction. Endocrinol Metab Clin North Am,2007,6（4）:105l-1066.
[3] Mandac JC,Chaudhry S,Sherman KE,et a1. The clinical and physiological spectrum of interferon-alpha induced thyroiditis:toward a new classification.Hepatology,2006,43（4）:661-672.
[4] 中华医学会内分泌学分会《中国甲状腺疾病诊治指南》编写组.甲状腺疾病诊治指南-甲状腺功能减退症.中华内科杂志,2007,46（11）:967-971.
[5] 中华医学会内分泌学分会《中国甲状腺疾病诊治指南》编写组.中国甲状腺疾病诊治指南-甲状腺功能亢进症.中华内科杂志,2007,46（10）:876-882.
[6] Orságová I, RoZnovsky L,Petrousová L,et al. Thyroid dysfunction during interferon alpha therapy for chronic hepatitis B and C-twenty years of experience. Klin Mikrobiol Infekc Lek,2014,20（3）:92-97.
[7] Hwang Y,Kim W,Kwon SY,et al. Incidence of and risk factors for thyroid dysfunction during peginterferon α and ribavirin treatment in patients with chronic hepatitis C. Korean J Intern Med, 2015,30（6）:792-800.
[8] 周红霞,赵斗贵,姜树勤,等.干扰素联合利巴韦林治疗慢性丙型肝炎致甲状腺功能异常临床分析. 中国肝脏病杂志（电子版）,2014,6（1）:71-74.
[9] 王晗,谢娜,徐军,等. 慢性丙型肝炎患者干扰素-α治疗后诱发甲状腺功能异常观察.解放军医学院学报,2015,12（11）:1089-1092.
[10] Prummel MF,Laurberg P. Interferon-alpha and autoimmune thyroiddisease. Thyroid,2003,13（6）:547-551.
[11] Moncoucy X,Leymarie F,Delemer B,et a1. Risk factors and long-term course of thyroid dysfunction during antiviral treatments in 221 patients with chronic hepatitis C. Gastroenterol Clin Biol,2005,29（4）:339-345.
[12] 方敏,邱国华,路遥,等.聚乙二醇化干扰素α-2a 联合利巴韦林治疗慢性丙型肝炎合并甲状腺功能紊乱一例.中华实验和临床感染病杂志（电子版）,2013,10（5）:739-740.
[13] 滕志兰,巩维进,张树青,等. 聚乙二醇干扰素α-2a联合利巴韦林治疗慢性丙型肝炎合并慢性淋巴细胞性甲状腺炎的临床观察. 中华肝脏病杂志,2013,21（2）:101-104.
[14] Tran HA,Jones TL,Janna EA,et al.The nature history of interferon-alpha induced thyroiditis in chronic hepatitis C patients;a long term study. Thyroid Res,2011,4（1）:2.
[15] Vasiliadis T,Anaqnostis P,Nalmpantidis G,et al.Thyroid dysfunction and long-term outcome during and after interferon-alpha therapy in patients with chronic hepatitis C. Ann Acad Med Sinqapore,2011,40（9）:394-400.
[16] Doi F,Kakizaki S,Takagi H,et al.Long-term outcome of interferon-alpha-induced autoimmune thyroid disorders in chronic hepatitis C. Liver Int,2005,25（2）:242-246.
[17] Carella C,Mazziotti G,Morisco F,et al. Long-term outcome of interferon-alpha-induced thyroid autoimmunity and prognostic influence of thyroid autoantibody pattern at the end of treatment. J Clin Endocrinol Metab,2001,86（5）:1925-1929.
[18] Tran HA,Jones TL,Gibson R,et al.Thyroid disease is a favorable prognostic factor in achieving sustained virologic response in chronic hepatitis C undergoing combination therapy:A nested case control study. BMC Endo Diso,2011,11:10.
[19] 马会乐,郭章林,邱国华,等.聚乙二醇化干扰素-α2a治疗慢性丙型肝炎并发甲状腺疾病患者的临床疗效观察.中国肝脏病杂志（电子版）,2013,5（2）:39-42.
[20] Barut S,Gunal O,Erkorkmaz U,et al.Thyroid dysfunction in Turkish patients with chronic hepatitis C receiving peginterferon plus ribavirin in the period of 2005-2010.Braz J Infect Dis,2012,16（5）:448-451.

抗丙型肝炎病毒治疗过程中甲状腺功能异常与病毒学应答关系研究^*

Prevalence of thyroid dysfunction and its impact on virologic response in patients with hepatitis C receiving pegylated interferon-α and ribavirin

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	张迎明, 申爽, 田飞, 孙园园. IFNL4和IL-28B基因多态性检测评估慢性乙型肝炎患者抗病毒治疗应答价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 828-831.
[2]	潘美民, 李文娟, 蒋芳清, 杨丽晖, 谭永卫, 何娟, 阮建文, 蔡春琳. 慢性丙型肝炎患者血清IL-17A、FGF和IL-7水平与丙型肝炎病毒感染自发清除临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(6): 840-843.
[3]	李传杰, 徐静, 王亮亮, 潘劲劲, 刘波. 恩替卡韦治疗慢性乙型肝炎患者血清HBsAg变化与病毒学应答的相关性研究[J]. 实用肝脏病杂志, 2019, 22(6): 928-929.
[4]	涂杰霞, 王安娜, 廖若汐. 干扰素α-2b与聚乙二醇干扰素α-2a治疗慢性乙型肝炎患者疗效比较研究*[J]. 实用肝脏病杂志, 2019, 22(5): 648-651.
[5]	邓浩辉, 李晓强, 高洪波, 陈伟烈. HIV/HCV混合感染者与HCV感染者感染HCV基因型分析*[J]. 实用肝脏病杂志, 2019, 22(5): 656-659.
[6]	袁春晖, 李春雨, 李红丽, 赵红娜, 王文红, 孟庆旭, 张中学. 国产聚乙二醇化干扰素α治疗HBeAg阳性慢性乙型肝炎患者疗效研究[J]. 实用肝脏病杂志, 2019, 22(3): 353-356.
[7]	刘立, 李俊义, 杜映荣, 刘春云, 李卫昆, 王辉, 李惠敏, 常丽仙, 祁燕伟. 索磷布韦/达拉他韦治疗慢性丙型肝炎患者疗效及安全性分析：一项真实世界研究[J]. 实用肝脏病杂志, 2019, 22(3): 361-364.
[8]	袁春晖,李春雨,李红丽,赵红娜,王文红,孟庆旭,张中学. IL28B基因多态性对聚乙二醇干扰素α治疗HBeAg阳性慢性乙型肝炎患者疗效的影响[J]. 实用肝脏病杂志, 2019, 22(2): 184-187.
[9]	蒋奕,刘冰. 慢性乙型肝炎与慢性丙型肝炎患者临床和肝组织病理学特征分析[J]. 实用肝脏病杂志, 2019, 22(2): 188-191.
[10]	吴静,东保吉,吴超. 慢性丙型肝炎患者外周血滤泡辅助性T淋巴细胞表面PD-1受体表达及意义研究^*[J]. 实用肝脏病杂志, 2019, 22(2): 192-195.
[11]	吴亚平,周冰清,蒋蓓莉. 慢性丙型肝炎患者发生重度肝纤维化相关因素分析^*[J]. 实用肝脏病杂志, 2019, 22(2): 196-199.
[12]	侯春阳, 马玉梅, 李方治. Peg-IFNα-2b联合利巴韦林治疗基因1/6型慢性丙型肝炎患者临床研究^*[J]. 实用肝脏病杂志, 2019, 22(1): 53-56.
[13]	曹艳平, 隋洪婷, 潘猛, 曲宝聚, 朴红心. 恩替卡韦联合聚乙二醇干扰素或胸腺素治疗代偿期乙型肝炎肝硬化2年疗效随访^*[J]. 实用肝脏病杂志, 2019, 22(1): 93-96.
[14]	周思思, 沈有秀, 李娟, 俞科贤. 慢性丙型肝炎和肝硬化患者外周血Th17和Treg细胞及其相关细胞因子水平变化^*[J]. 实用肝脏病杂志, 2018, 21(5): 689-692.
[15]	曹风华, 经继生, 赵伟, 江英骙, 马洁. 大剂量普通α-干扰素与聚乙二醇化α-干扰素联合利巴韦林治疗慢性丙型肝炎患者临床疗效及安全性比较研究^*[J]. 实用肝脏病杂志, 2018, 21(5): 729-732.